Isabelle C, Boles A, McConnell K, Keller R, Burzinski R, Hutchins Z
Leukemia. 2025; .
PMID: 40057636
DOI: 10.1038/s41375-025-02551-4.
Horenstein A, Faini A, Morandi F, Ortolan E, Storti P, Giuliani N
Front Immunol. 2025; 16:1519300.
PMID: 40013150
PMC: 11860881.
DOI: 10.3389/fimmu.2025.1519300.
Diaz-Tejedor A, Rodriguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, Gonzalez-Rodriguez M, Castellanos B
Int J Mol Sci. 2024; 25(9).
PMID: 38731936
PMC: 11083018.
DOI: 10.3390/ijms25094718.
Pu J, Liu T, Wang X, Sharma A, Schmidt-Wolf I, Jiang L
Exp Hematol Oncol. 2024; 13(1):45.
PMID: 38654286
PMC: 11040994.
DOI: 10.1186/s40164-024-00507-5.
Liu J, Xing L, Li J, Wen K, Liu N, Liu Y
Nat Commun. 2024; 15(1):1367.
PMID: 38355622
PMC: 10866908.
DOI: 10.1038/s41467-024-45561-z.
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N
Leukemia. 2023; 37(9):1925-1928.
PMID: 37532787
PMC: 10457196.
DOI: 10.1038/s41375-023-01983-0.
Cytokine receptor IL27RA is an NF-κB-responsive gene involved in CD38 upregulation in multiple myeloma.
Brownlie R, Kennedy R, Wilson E, Milanovic M, Taylor C, Wang D
Blood Adv. 2023; 7(15):3874-3890.
PMID: 36867577
PMC: 10405202.
DOI: 10.1182/bloodadvances.2022009044.
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD-Lowering Agents.
Becherini P, Soncini D, Ravera S, Gelli E, Martinuzzi C, Giorgetti G
Antioxidants (Basel). 2023; 12(2).
PMID: 36830052
PMC: 9952390.
DOI: 10.3390/antiox12020494.
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse R
Front Oncol. 2022; 12:1020011.
PMID: 36387095
PMC: 9646612.
DOI: 10.3389/fonc.2022.1020011.
Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.
Mustafa N, Azaman M, Ng G, Chng W
Biomolecules. 2022; 12(9).
PMID: 36139103
PMC: 9496523.
DOI: 10.3390/biom12091261.
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong J, Ning Z, Pan D, Fu X, Lu X
Front Pharmacol. 2022; 13:932914.
PMID: 36120308
PMC: 9481063.
DOI: 10.3389/fphar.2022.932914.
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson I, Patino-Escobar B, Tuomivaara S, Lin Y, Nix M, Leung K
Nat Commun. 2022; 13(1):4121.
PMID: 35840578
PMC: 9287322.
DOI: 10.1038/s41467-022-31810-6.
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
Wu H, Zhao X
Int J Biol Sci. 2022; 18(5):1974-1988.
PMID: 35342342
PMC: 8935232.
DOI: 10.7150/ijbs.68148.
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho S, Xing L, Anderson K, Tai Y
Cancers (Basel). 2021; 13(23).
PMID: 34885245
PMC: 8657018.
DOI: 10.3390/cancers13236136.
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.
Frerichs K, Minnema M, Levin M, Broijl A, Bos G, Kersten M
Blood Adv. 2021; 5(23):5128-5139.
PMID: 34625791
PMC: 9153006.
DOI: 10.1182/bloodadvances.2021005220.
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.
Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L
Front Oncol. 2021; 11:684561.
PMID: 34307150
PMC: 8297441.
DOI: 10.3389/fonc.2021.684561.
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
Mustafa N, Nee A, Chooi J, Toh S, Chung T, Selvarajan V
J Immunother Cancer. 2021; 9(7).
PMID: 34215687
PMC: 8256838.
DOI: 10.1136/jitc-2020-002123.
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J
Hemasphere. 2021; 5(7):e596.
PMID: 34131635
PMC: 8196092.
DOI: 10.1097/HS9.0000000000000596.
Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.
Yang T, Yang Y, Wang Y
Clin Epigenetics. 2021; 13(1):113.
PMID: 34001246
PMC: 8130364.
DOI: 10.1186/s13148-021-01098-2.
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression.
Diaz-Tejedor A, Lorenzo-Mohamed M, Puig N, Garcia-Sanz R, Mateos M, Garayoa M
Cancers (Basel). 2021; 13(6).
PMID: 33802806
PMC: 8002455.
DOI: 10.3390/cancers13061353.
